人民卫生出版社系列期刊
ISSN 2096-2738 CN 11-9370/R

中国科技核心期刊(中国科技论文统计源期刊)
中国科学引文数据库(CSCD)来源期刊
《中国学术期刊影响因子年报》统计源期刊
美国化学文摘社(CAS)数据库收录期刊
日本科学技术振兴机构(JST)数据库收录期刊

新发传染病电子杂志 ›› 2025, Vol. 10 ›› Issue (6): 16-23.doi: 10.19871/j.cnki.xfcrbzz.2025.06.003

• WHO结核病报告和指南解读 • 上一篇    下一篇

《WHO结核病整合指南模块4:治疗与关怀》的实践溯源与应用思考

吴迪1, 刘志辉2, 杨佳诺1, 陈亮1   

  1. 1.广州市胸科医院结核病科,广东 广州 510095;
    2.广州市胸科医院医学检验科,广东 广州 510095
  • 收稿日期:2025-06-01 出版日期:2025-12-31 发布日期:2026-01-26
  • 通讯作者: 陈亮,Email:18928929722@126.com
  • 基金资助:
    广州市医学重点学科(2025-2027)结核病学

Practical origins and application considerations of the WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment Care and Support

Wu Di1, Liu Zhihui2, Yang Jianuo1, Chen Liang1   

  1. 1. Department of Tuberculosis, Guangzhou Chest Hospital, GuangDong Guangzhou 510095, China;
    2. Department of Clinical Laboratory, Guangzhou Chest Hospital, GuangDong Guangzhou 510095, China
  • Received:2025-06-01 Online:2025-12-31 Published:2026-01-26

摘要: WHO于2025年4月15日正式发布《WHO结核病整合指南模块4:治疗与关怀》,该指南突破既往分领域指导的模式,将结核病患者的治疗与关怀体系进行有机整合,构建了一体化的临床实践框架。其修订基础源于WHO 2022年发布的3部相关指南,包括《WHO结核病整合指南模块4:药物敏感结核病治疗》《WHO结核病整合指南模块4:耐结核病治疗2022年更新版》及《WHO结核病整合指南模块4:结核病关怀与支持》,同时系统融入了结核病诊疗领域的最新研究成果,核心更新内容聚焦于基于两项关键临床试验证据形成的利福平耐药肺结核6个月与9个月治疗方案,为耐药结核病的短程治疗提供了新的循证医学依据。该指南不仅是临床决策与疾病控制的重要参考,更对实践应用提出了全方位、深层次的思考要求。为实现指南的高效落地与创新应用,需深入追溯其实践基础,精准把握核心要旨并结合临床实际进行灵活实施。本文从指南核心要旨解读、实践溯源分析及临床应用思考3个维度展开系统探讨,为结核病相关工作者精准理解与科学应用指南提供参考,助力推动全球“终结结核病”目标的实现。

关键词: 结核病, 指南, 抗结核治疗, 人文关怀, 社会支持, 实践溯源

Abstract: On April 15, 2025, the WHO officially released the WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment and Care. This guideline represents a significant departure from the previous domain-specific guidance model. By organically integrating the treatment and care systems for tuberculosis patients, it constructs an integrated clinical practice framework. Based on three relevant guidelines issued in 2022, including WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment of Drug-Susceptible Tuberculosis, WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment of Drug-Resistant Tuberculosis (2022 Update), and WHO Consolidated Guidelines on Tuberculosis, Module 4: Tuberculosis Care and Support, this guideline systematically incorporates the latest research achievements in the field of tuberculosis diagnosis and treatment. Its core updated content focuses on the 6-month and 9-month treatment regimens for rifampicin-resistant pulmonary tuberculosis formed on the basis of two key clinical trials providing new evidence-based medical basis for the short-course treatment of drug-resistant tuberculosis.For tuberculosis control workers and clinical medical staff, this guideline not only serves as an important reference for clinical decision-making and disease control but also puts forward requirements for comprehensive and in-depth thinking on its practical application. To realize the efficient implementation and innovative application of the guideline, it is necessary to thoroughly trace its practical foundation and developmental process, accurately grasp its core tenets, and flexibly apply it in combination with clinical practice. This paper intends to conduct a systematic discussion from three dimensions: interpretation of the guideline's core tenets, analysis of its practical origin, and reflections on its clinical application, aiming to provide references for tuberculosis-related workers to accurately understand and scientifically apply the guideline and help promote the achievement of the global goal of "ending tuberculosis". The practice traceability analysis of the recommended regimens will be highly beneficial for clinical applications. This paper will conduct an in depth exploration from three perspectives: the key points of the guidelines, the practice traceability, and the considerations regarding application.

Key words: Tuberculosis, Guidelines, Anti-tuberculosis treatment, Human-centered care, Social support, Practical origins

中图分类号: